Cargando…
Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema
Background: Hereditary angioedema (HAE) due to C1 inhibitor (C1INH) deficiency is characterized by recurrent attacks of edema of the skin and mucosal tissues. Symptoms usually present during childhood (mean age at first attack, 10 years). Earlier symptom onset may predict a more severe disease cours...
Autores principales: | Levy, Donald, Caballero, Teresa, Hussain, Iftikhar, Reshef, Avner, Anderson, John, Baker, James, Schwartz, Lawrence B., Cicardi, Marco, Prusty, Subhransu, Feuersenger, Henrike, Pragst, Ingo, Manning, Michael E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499895/ https://www.ncbi.nlm.nih.gov/pubmed/32953229 http://dx.doi.org/10.1089/ped.2020.1143 |
Ejemplares similares
-
Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial
por: Levy, Donald S., et al.
Publicado: (2020) -
Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
por: Li, H. Henry, et al.
Publicado: (2019) -
Patterns of on-demand medication use in patients with hereditary angioedema treated long-term with prophylactic subcutaneous C1-inhibitor
por: Levy, Donald S., et al.
Publicado: (2019) -
Biomarkers in Hereditary Angioedema
por: Porebski, Grzegorz, et al.
Publicado: (2021) -
Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema
por: Zhang, Ying, et al.
Publicado: (2018)